Gene expression in circulating tumor cells reveals a dynamic role of EMT and PD-L1 during osimertinib treatment in NSCLC patients
Abstract Liquid biopsy is a tool to unveil resistance mechanisms in NSCLC. We studied changes in gene expression in CTC-enriched fractions of EGFR-mutant NSCLC patients under osimertinib. Peripheral blood from 30 NSCLC patients before, after 1 cycle of osimertinib and at progression of disease (PD)...
Main Authors: | Aliki Ntzifa, Areti Strati, Galatea Kallergi, Athanasios Kotsakis, Vassilis Georgoulias, Evi Lianidou |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-01-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-82068-9 |
Similar Items
-
Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
by: Aliki Ntzifa, et al.
Published: (2021-05-01) -
Prognostic Significance of <i>TWIST1</i>, <i>CD24</i>, <i>CD44</i>, and <i>ALDH1</i> Transcript Quantification in EpCAM-Positive Circulating Tumor Cells from Early Stage Breast Cancer Patients
by: Areti Strati, et al.
Published: (2019-06-01) -
CD8 PD-1 T-cells and PD-L1 circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?
by: Athanasios Kotsakis, et al.
Published: (2019-06-01) -
RNA-Based CTC Analysis Provides Prognostic Information in Metastatic Breast Cancer
by: Areti Strati, et al.
Published: (2021-03-01) -
Evaluation of PD-L1/PD-1 on circulating tumor cells in patients with advanced non-small cell lung cancer
by: Galatea Kallergi, et al.
Published: (2018-01-01)